{
    "clinical_study": {
        "@rank": "104079", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be given on Day 1 orally"
            }, 
            {
                "arm_group_label": "Vitamin D", 
                "arm_group_type": "Active Comparator", 
                "description": "Administration of 500,000 IU Vitamin D orally on Day 1"
            }
        ], 
        "brief_summary": {
            "textblock": "Chronic liver diseases are associated with inflammation.  The investigators postulate that\n      Vitamin D may modulate inflammation.  Thus the investigators will study the effect of\n      Vitamin D replacement in patients with Hepatitis C infection and Vitamin D deficiency."
        }, 
        "brief_title": "Effects of Vitamin D on Inflammation in Liver Disease", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatitis C Infection", 
            "Vitamin D Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Inflammation", 
                "Liver Diseases", 
                "Vitamin D Deficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "Vitamin D appears to be a critical signaling molecule for macrophages because is needed for\n      activation and differentiation of monocytes/macrophages.   From our Preliminary Studies( VA\n      Merit Review Grant), we propose that Vitamin D deficiency may alter the 'pro-inflammatory'\n      ('classically activated') M1 macrophages , characterized by   i] high expression of NOS2,\n      TNF-a, IL-1, IL-6, IL-8, TGF-a, CXCL10, and CCL19; and  ii] minimal expression of arginase 1\n      and mannose R.\n\n      The clinical relevance of these findings is suggested by the presence of activated   M1\n      macrophages in liver biopsies from patients with severe drug-induced liver injury\n      (unpublished observations).\n\n      Prospective vitamin D supplementation studies with appropriate endpoints are needed to\n      define the role of vitamin D on inflammation in patients with chronic liver diseases."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women aged 18 or older\n\n          -  Total 25-OH Vit D < 25 ng/mL\n\n          -  Infection with HCV genotype 1 (subjects infected with multiple genotypes are not\n             eligible).\n\n          -  Plasma HCV RNA concentration of >100,000 IU/mL.\n\n          -  HCV-infected subjects na\u00efve to treatment: subjects who either have never been treated\n             for HCV infection or who previously received HCV treatment ending > 3 months prior to\n             enrollment (including, any IFN-Alpha with or without ribavirin, or other anti-HCV\n             antiviral medication).\n\n        Exclusion Criteria:\n\n          -  Women who are pregnant or breastfeeding.\n\n          -  Patients with Sarcoidosis, Histoplasmosis, Lymphoma, Primary Hyperparathyroidism or\n             Idiophatic Hypercalcemia.\n\n          -  Liver Cirrhosis.\n\n          -  Known active gastrointestinal disease that could interfere with the absorption of the\n             test article.\n\n          -  Laboratory determinations at screening as follows:\n\n          -  Hemoglobin <10 g/dL .\n\n          -  Serum creatinine that is not within normal limits.  However, such subjects may be\n             enrolled if the Cockroft-Gault glomerular filtration rate (GFR) is > 50 mL/minute.\n\n          -  Unstable hypertension, cardiac disease or type 2 diabetes requiring changes in\n             treatment with medications 4 weeks prior to screening or during the screening period.\n\n          -  Use of an investigational drug within 4 weeks before the screening visit or during\n             the screening period.\n\n          -  Use of systemic immunosuppressants (including systemic, oral, or intravenous\n             corticosteroids) or immunomodulating agents within 4 weeks before the screening visit\n             or during the screening period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 17, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754961", 
            "org_study_id": "UCSD-111219"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamin D", 
                "description": "Vitamin D 500,000 IU given orally on Day 1", 
                "intervention_name": "Vitamin D", 
                "intervention_type": "Drug", 
                "other_name": "Vitamin D Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo given orally on Day 1", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Emulsion placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 18, 2012", 
        "location": {
            "contact": {
                "email": "kcinocencio@ucsd.edu", 
                "last_name": "Kim Inocencio, BS", 
                "phone": "619-717-1906"
            }, 
            "facility": {
                "address": {
                    "city": "La Jolla", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92093"
                }, 
                "name": "UC San Diego, CTRI"
            }, 
            "investigator": {
                "last_name": "Mario Chojkier, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Vitamin D on Inflammation in Liver Disease", 
        "overall_contact": {
            "email": "kcinocencio@ucsd.edu", 
            "last_name": "Kim Inocencio, BS", 
            "phone": "619-717-1906"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Diego", 
            "last_name": "Mario Chojkier, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "As determined by serum levels and macrophage cytokine production compared to placebo and baseline", 
            "measure": "Macrophage activation", 
            "safety_issue": "No", 
            "time_frame": "one week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754961"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Veterans Medical Research Foundation", 
            "investigator_full_name": "Mario Chojkier", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Measurement of ALT/AST", 
            "measure": "Liver injury", 
            "safety_issue": "Yes", 
            "time_frame": "one week"
        }, 
        "source": "Veterans Medical Research Foundation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Veterans Medical Research Foundation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}